institute/how we support ourselves

How we support ourselves

For over fifty years, the Mario Negri Institute has conducted its research, training and the dissemination of information in accordance with its core values of independence, commitment to the scientific method and respect for ethics. For this reason, we have chosen to finance ourselves autonomously.

The institute accepts research funding regardless of whether it originates from the public or private sector and from commercial or non-profit entities, with the exception of funds that are intended to support the promotion of commercial products or to support anti-science ideologies or approaches that could have adverse effects on public and individual health.

The basic criteria for research projects are:
- That the studies be performed autonomously.
- That the data be owned by the institute until publication.
- That third-party rights with regards to patentability be respected.

Every researcher, according to their level of seniority, is responsible for obtaining the necessary fundsfor their own research and, at the same time, must use these resources appropriately.

In general, the Mario Negri Pharmacological Research Institute does not accept funding – from anysingle source – that exceeds 10% of its annual budget, to avoid being subject to undue influence.


DATA FROM 2018

FUNDS OBTAINED IN 2018
USE OF FUNDS IN 2018

Data from 2019 will be published soon.


DATA RELATING TO RESEARCH CONDUCTED IN 2018

274

RESEARCH PROJECTS

373

SCIENTIFIC PUBLICATIONS

2.744

TOTAL IMPACT FACTOR*

*The impact factor reflects the average annual number of citations that articles published in the last two years have received in journals.


FIELDS OF RESEARCH FOR PROJECTS CARRIED OUT IN 2018


Cardiac diseases

  • Heart failure in elderly patients with comorbidities
  • Primary and secondary prevention of cardiovascular diseases
  • Estimated cardiovascular risk
  • Cardiopulmonary resuscitation
  • Cardiac amyloidosis

Oncology

  • Breast cancer
  • Lung cancer
  • Pancreatic cancer
  • Thymus cancer
  • Ovarian cancer
  • Sarcomas
  • Cachexia in cancer patients
  • Gastric cancer
  • Cancer of the fallopian tubes
  • Platinum-resistant primitive peritoneal cancer
  • Pleural mesothelioma
  • Renal metastatic cancer

Rare Diseases

  • Atypical haemolytic uremic syndrome
  • Thrombotic thrombocytopenic purpura
  • Membranous nephropathy
  • Polycystic kidney disease
  • Fibronectin glomerulopathy
  • Focal segmental glomerulosclerosis
  • Proliferative membrane glomerulonephritis
  • C3 glomerulopathy
  • Cavernous angioma
  • Fatal insomnia
  • Haemophilia A
  • Myelodysplastic syndromes
  • Steroid-resistant nephrotic syndrome
  • Steroid-sensitive nephrotic syndrome
  • Rett syndrome
  • Angelman syndrome

Renal diseases

  • Diabetic and non-diabetic nephropathies
  • Chronic nephropathy
  • Acute renal damage
  • Cardiovascular complications in nephropathic patients
  • Immunology of organ transplantation

Nervous system diseases

  • ALS
  • Spinal muscular atrophy
  • Prion diseases
  • Alzheimer’s disease
  • Ring chromosome 14 syndrome
  • Epilepsy
  • Ischemia
  • Neuroinflammation
  • Age-related neurodegenerative diseases
  • Mental health

Pollution and Health

  • The impact of toxic substances on human health (braking systems, biocides, materials thatcome into contact with food, dispersants, solvents, petroleum derivatives, cosmetics,perfluoroalkyl substances)
  • Exposure to passive smoke
  • Substance abuse (including psychoactive drugs)
  • Health effects from noise (tinnitus)
  • Food safety
  • Development of alternatives to animal testing

Public Health

  • Attention deficit hyperactivity disorder (ADHD)
  • Breast cancer screening, awareness raising
  • Developmental psychopathology
  • Appropriateness of medicine prescribing

Others research areas

  • Rheumatoid arthritis
  • Septic Shock
  • Glaucoma

Tieniti aggiornato sulle novità dell'Istituto Mario Negri. 

Iscriviti alla newsletter
Pagina Inglese